Insufficient financing
The company states that available liquidity may not fund operations beyond the beginning of 2027.
- Scope
- Clinical development continuity
- Materiality
- high
Mendus
Mendus AB is a Swedish clinical-stage biopharmaceutical company focused on developing immunotherapies for myeloid blood cancers. Its lead asset, vididencel, is being developed in multiple leukemia settings through the company’s subsidiaries and research collaborations, with operations centered in Stockholm and R&D activities in Leiden and Australia.
20
2.69
2.47
| % | |
|---|---|
| Lead immunotherapy candidate | 100% Vididencel-based therapeutic development for myeloid malignancies. |
Mendus does not sell a commercial product base in the traditional sense; its primary counterparties are clinical...
- Clinical trial investigators and sitesprimary
Hospitals and trial centers that enroll patients into vididencel studies in AML and CML.
- Research collaboratorssecondary
Institutes such as ONJCRI that support trial execution, biomarker work, and clinical research.
- Licensing and collaboration partnersprimary
Biopharma partners that may fund, co-develop, or commercialize the asset in selected territories or indications.
- Future treating physicians and oncology centersemerging
Specialist hematology-oncology centers that would use the therapy if it reaches commercialization.
Mendus is headquartered in Stockholm, Sweden, with R&D offices in Leiden, the Netherlands, and an Australian subsidiary...
- •Head office in Stockholm, Sweden
- •R&D office in Leiden, the Netherlands
- •Australian subsidiary supports clinical development
- •Clinical and regulatory activity is multinational
- •No disclosed product revenue by country
Mendus is focused on advancing vididencel through parallel clinical paths in AML and CML to broaden the asset’s...
01
Advance vididencel in AMLshort-term
AML is the core development area and a key proof point for the platform.
02
Start and expand CML developmentshort-term
A second indication can broaden the addressable market and de-risk the asset.
03
Pursue collaborations and licensingmedium-term
External partners can provide capital, expertise, and commercialization reach.
Mendus is exposed to the high failure rate and long timelines typical of clinical-stage biotech, where trial outcomes...
Clinical development risk
Vididencel must show efficacy and safety in AML and CML trials before value can be realized.
- Scope
- DIVA and VITAL-CML programs
- Materiality
- high
Regulatory and reimbursement risk
Approval and reimbursement regimes can affect trial progression and future market access.
- Scope
- Future commercialization
- Materiality
- medium
Intellectual property dependence
The asset’s commercial value depends on patent and know-how protection.
- Scope
- Vididencel platform
- Materiality
- high
Going concern and liquidity assessment
Affects valuation of the company and interpretation of the financial statements
Warrants and share-based remuneration
Can distort period-to-period comparability of operating loss
Fair value of financial instruments
Affects liabilities, trade payables, and financing-related disclosures
Acquisition accounting for subsidiaries
Influences consolidation balances and equity presentation
: 11/08/2026